CalciMedica Inc (CALC)

Currency in USD
1.995
+0.025(+1.27%)
Real-time Data·
CALC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.9301.998
52 wk Range
1.87036.000
Key Statistics
Prev. Close
1.97
Open
1.98
Day's Range
1.93-1.998
52 wk Range
1.87-36
Volume
12.68K
Average Volume (3m)
276.71K
1-Year Change
-87.5701%
Book Value / Share
1.74
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CALC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
50.000
Upside
+2,406.27%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

CalciMedica Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral

Analyst Ratings

3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 50.000
(+2,406.27% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Guggenheim
Buy9.00+351.13%-New CoverageAug 20, 2026
Guggenheim
Buy9.00+351.13%-New CoverageAug 20, 2026
H.C. Wainwright
Hold---MaintainAug 13, 2026
Oppenheimer
Buy10.00+401.25%20.00MaintainMar 05, 2026
H.C. Wainwright
Hold---DowngradeJan 29, 2026

Earnings

Latest Release
Aug 11, 2026
EPS / Forecast
-2.25 / -1.30
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

CALC Income Statement

Compare CALC to Peers and Sector

Metrics to compare
CALC
Peers
Sector
Relationship
P/E Ratio
−0.6x−2.7x−0.4x
PEG Ratio
−0.04−0.050.00
Price/Book
2.4x2.1x2.6x
Price / LTM Sales
-7.0x3.0x
Upside (Analyst Target)
-180.7%55.0%
Fair Value Upside
Unlock2.2%7.6%Unlock

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
42.57K0.62%84.29K
Other Institutional Investors
5.56M81.35%11.00M
Public Companies & Retail Investors
1.23M18.02%2.44M
Total
6.83M100.00%13.52M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Alafi Capital Company LLC14.97%1,022,4692,024
Sanderling Ventures7.78%531,2291,052

People Also Watch

7.360
GTBP
-1.74%
10.180
BIAF
+16.34%
1.9550
TENX
+5.11%
4.1300
TNON
-1.67%
0.900
NUWE
-17.44%

FAQ

What Is the CalciMedica (CALC) Stock Price Today?

The CalciMedica stock price today is 1.995 USD.

What Stock Exchange Does CalciMedica Trade On?

CalciMedica is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for CalciMedica?

The stock symbol for CalciMedica is "CALC."

What Is the CalciMedica Market Cap?

As of today, CalciMedica market cap is 13.460M USD.

What Is CalciMedica's Earnings Per Share (TTM)?

The CalciMedica EPS (TTM) is -6.653.

When Is the Next CalciMedica Earnings Date?

CalciMedica will release its next earnings report on Nov 18, 2026.

From a Technical Analysis Perspective, Is CALC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has CalciMedica Stock Split?

CalciMedica has split 2 times.

How Many Employees Does CalciMedica Have?

CalciMedica has 15 employees.

What is the current trading status of CalciMedica (CALC)?

As of Sep 18, 2026, CalciMedica (CALC) is trading at a price of 1.995 USD, with a previous close of 1.970 USD. The stock has fluctuated within a day range of 1.930 USD to 1.998 USD, while its 52-week range spans from 1.870 USD to 36.000 USD.

What Is CalciMedica (CALC) Price Target According to Analysts?

The average 12-month price target for CalciMedica is 50.000 USD, with a high estimate of 75 USD and a low estimate of 30 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +2,406.27% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.